Skip to main content
. 2020 Oct;8(20):1301. doi: 10.21037/atm-20-6181

Table 2. Efficacy evaluation.

Variables Values
Median follow-up (months), median (IQR) 14.3 (12.3–19.3)
Median duration of treatment (months), median (IQR) 4.8 (2.0–8.8)
Median RFS (months) (95% CI) 7.6 (5.7–9.5)
1-year RFS rate (%) 36.1
1-year OS rate (%) 93.3

IQR, interquartile range; LCSGJ, Liver Cancer Study Group of Japan; OS, overall survival PVTT, portal vein tumor thrombosis; RFS, recurrence-free survival.